227 related articles for article (PubMed ID: 32875598)
1. Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms.
Jafarzadeh A; Jafarzadeh S; Nozari P; Mokhtari P; Nemati M
Scand J Immunol; 2021 Feb; 93(2):e12967. PubMed ID: 32875598
[TBL] [Abstract][Full Text] [Related]
2. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
3. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.
Reche PA
Front Immunol; 2020; 11():586984. PubMed ID: 33178220
[TBL] [Abstract][Full Text] [Related]
4. Lymphopenia in COVID-19: Therapeutic opportunities.
Fathi N; Rezaei N
Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
[TBL] [Abstract][Full Text] [Related]
5. Convalescent Memory T Cell Immunity in Individuals with Mild or Asymptomatic SARS-CoV-2 Infection May Result from an Evolutionarily Adapted Immune Response to Coronavirus and the 'Common Cold'.
Stefano GB; Kream RM
Med Sci Monit; 2020 Nov; 26():e929789. PubMed ID: 33239605
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING?
Berthelot JM; Lioté F; Maugars Y; Sibilia J
Front Immunol; 2020; 11():607069. PubMed ID: 33335532
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147.
Shouman S; El-Kholy N; Hussien AE; El-Derby AM; Magdy S; Abou-Shanab AM; Elmehrath AO; Abdelwaly A; Helal M; El-Badri N
Cell Commun Signal; 2024 Jul; 22(1):349. PubMed ID: 38965547
[TBL] [Abstract][Full Text] [Related]
8. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.
Xu W; Wang M; Yu D; Zhang X
Front Immunol; 2020; 11():565278. PubMed ID: 33013929
[TBL] [Abstract][Full Text] [Related]
9. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.
Naz A; Shahid F; Butt TT; Awan FM; Ali A; Malik A
Front Immunol; 2020; 11():1663. PubMed ID: 32754160
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs.
Xiang Q; Feng Z; Diao B; Tu C; Qiao Q; Yang H; Zhang Y; Wang G; Wang H; Wang C; Liu L; Wang C; Liu L; Chen R; Wu Y; Chen Y
Front Immunol; 2021; 12():661052. PubMed ID: 33995382
[TBL] [Abstract][Full Text] [Related]
11. The Science Underlying COVID-19: Implications for the Cardiovascular System.
Liu PP; Blet A; Smyth D; Li H
Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations.
Farshadpour F; Taherkhani R
Med Princ Pract; 2021; 30(5):422-429. PubMed ID: 33882487
[TBL] [Abstract][Full Text] [Related]
13. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.
Oliveira SC; de Magalhães MTQ; Homan EJ
Front Immunol; 2020; 11():587615. PubMed ID: 33193414
[TBL] [Abstract][Full Text] [Related]
14. The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.
Delshad M; Tavakolinia N; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bagheri N; Bashash D
Int Immunopharmacol; 2021 Jun; 95():107586. PubMed ID: 33765611
[TBL] [Abstract][Full Text] [Related]
15. Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications.
An PJ; Zhu YZ; Yang LP
Pharmacol Res; 2020 Sep; 159():104946. PubMed ID: 32450346
[TBL] [Abstract][Full Text] [Related]
16. Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.
Rakib A; Sami SA; Mimi NJ; Chowdhury MM; Eva TA; Nainu F; Paul A; Shahriar A; Tareq AM; Emon NU; Chakraborty S; Shil S; Mily SJ; Ben Hadda T; Almalki FA; Emran TB
Comput Biol Med; 2020 Sep; 124():103967. PubMed ID: 32828069
[TBL] [Abstract][Full Text] [Related]
17. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
18. Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes.
Jain N; Shankar U; Majee P; Kumar A
Infect Genet Evol; 2021 Jan; 87():104648. PubMed ID: 33264668
[TBL] [Abstract][Full Text] [Related]
19. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
